High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis

Dalia Rotstein, Colleen Maxwell, Karen Tu, Jodi Gatley, Priscila Pequeno, Alexander Kopp and Ruth Ann Marrie

Abstract

Background: Multiple sclerosis (MS) has been associated with certain comorbidities in general population studies, but it is unknown how comorbidity may affect immigrants with MS.

Objective: To compare prevalence of comorbidities in immigrants and long-term residents at MS diagnosis, and in matched control populations without MS.

Methods: We identified incident MS cases using a validated definition applied to health administrative data in Ontario, Canada, from 1994 to 2017, and categorized them as immigrants or long-term residents. Immigrants and long-term residents without MS (controls) were matched to MS cases 3:1 on sex, age, and geography.

Results: There were 1534 immigrants and 23,731 long-term residents with MS matched with 4585 and 71,193 controls, respectively. Chronic obstructive pulmonary disease (COPD), diabetes, hypertension, ischemic heart disease, migraine, epilepsy, mood/anxiety disorders, schizophrenia, inflammatory bowel disease (IBD), and rheumatoid arthritis were significantly more prevalent among immigrants with MS compared to their controls. Prevalence of these conditions was generally similar comparing immigrants to long-term residents with MS, although COPD, epilepsy, IBD, and mood/anxiety disorders were less prevalent in immigrants.

Conclusion: Immigrants have a high prevalence of multiple comorbidities at MS diagnosis despite the “healthy immigrant effect.” Clinicians should pay close attention to identification and management of comorbidity in immigrants with MS.

Keywords: Multiple sclerosis, immigrants, comorbidity, prevalence

Date received: 7 February 2021; revised: 5 June 2021; accepted: 15 June 2021

Introduction

Comorbidity is common at multiple sclerosis (MS) diagnosis, as has been shown in studies in Canada, the United Kingdom, and the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry in the United States. Particular conditions associated with MS include vascular diseases, mood and anxiety disorders, chronic lung disease, and epilepsy, although there is some variability in associations between specific conditions and MS across regions. Comorbidity is associated with earlier disability progression in MS, and may contribute to worse prognosis in affected individuals. In previous studies, comorbidity at MS diagnosis was more prevalent in those with later disease onset, and the comorbidity patterns differed in women versus men. It is not well known whether comorbidities may differentially affect other special populations with MS, including immigrants. Previously, we showed that total comorbidity burden was associated with a higher risk of MS in immigrants to Ontario, Canada, but did not characterize individual comorbidities.

Our objective was to identify specific comorbidities common in immigrants at MS diagnosis, and compare the prevalence of specific chronic conditions in immigrants with MS, immigrants without MS, and long-term residents with and without MS. We studied this question in Ontario, Canada, a region with universal health insurance and centralized collection of health
administrative data, and a large, diverse population of immigrants.

**Methods**

**Setting**

Ontario is the most populous province in Canada, with a population of more than 13 million. This was a retrospective matched cohort study using prospectively collected health administrative data. The data were collected through the universal Ontario Health Insurance Plan (OHIP) which is a publicly funded program that covers hospitalizations, outpatient physician visits without user fees, and outpatient prescription medications for persons aged 65+ years and those on social assistance. Most immigrants are eligible for OHIP coverage after a 3-month wait period; convention refugees are exempt from this wait period.

**Data sources**

Datasets were linked by unique encoded identifiers and analyzed at ICES as previously described. ICES (formerly known as the Institute for Clinical Evaluative Sciences) is an independent, non-profit research institute whose legal status under Ontario’s health information privacy law allows it to collect and analyze healthcare and demographic data, without consent, for health system evaluation and improvement. Data concerning immigrants arriving in Canada since 1985 are captured by the Immigration Refugees and Citizenship Canada’s (IRCC) electronic Permanent Resident Database. Long-term residents were defined for this study as individuals born in Ontario or moved to Ontario prior to 1985. This approach has been used in several previous studies of immigrants in Ontario. Immigrant data from the IRCC have been linked to the Registered Persons Database in Ontario and provincial health administrative databases using probabilistic matching.

**MS cases**

Cases were identified using a validated, previously published algorithm applied to health administrative billing data. Briefly, the algorithm required one hospitalization, or one emergency department visit, or at least five outpatient visits for MS (International Classification of Disease (ICD)-9/10-CA diagnosis codes 340/G35) over a 2-year period. Both primary and secondary discharge diagnoses of MS (340/G35) were included for hospitalizations. The index date was determined by the first in-patient or outpatient visit for a demyelinating condition as indicated by ICD-9/10-CA diagnosis codes, including encephalomyelitis (323/G36 or G37), optic neuritis (377/H46), or MS (340/G35), in all those who later met the predefined algorithm.

Incident MS cases were identified between 1 April 1994 and 31 March 2018. OHIP eligibility of at least 3 years was required for cohort selection to ensure sufficient history to meet comorbidity algorithms and to ensure that prevalent MS cases were not mistaken as incident. Cases were required to be between 20 and 65 years inclusive. The lower limit on age was chosen because of the lack of validation of comorbidity definitions in children. The upper limit on age was applied because of the rarity of incident MS at age > 65 years and concerns regarding possible misdiagnosis in this age bracket. Individuals were excluded if Ontario residence could not be confirmed.

Incident MS cases were stratified into immigrant and long-term resident groups.

**Controls**

Two control groups were defined separately for the immigrant and long-term resident groups and matched to cases 3:1. Controls were randomly selected from immigrants and long-term residents, respectively, who had no code for a demyelinating condition before or on the index date, including any code for MS, optic neuritis, or encephalomyelitis. Controls were matched to cases at index date based on age ± 2 years, sex, and place of residence (urban vs rural).

**Comorbidities**

Specific chronic conditions examined were selected from previous literature regarding comorbidities prevalent in individuals with MS. Comorbidities were defined based on previously validated algorithms applied to health administrative data over the 3 years prior to the MS index date (Table 1); this time window was utilized because of the limited OHIP history available in many of the immigrants. Thus, we were able to capture recent active comorbid conditions but not remote conditions where the algorithm would not have been met within the 3 years prior to MS index date. The selected conditions included: chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, hypertension, epilepsy, inflammatory bowel disease (IBD), ischemic heart disease (IHD), migraine, mood and anxiety disorders, rheumatoid arthritis (RA), and schizophrenia. Mood and anxiety disorders were grouped together because of overlapping codes for these disorders in Ontario.
Table 1. Individual comorbidity algorithms and data sources.

| Comorbidity                              | Years required for case definition (e.g. 1, 2, or 3) | ICD-9/10-CA codes | OHIP diagnostic/fee codes | Case definition: number and type of claims (hospitalization (H) or physician (P)) | Data sources | Comments                                                                 |
|------------------------------------------|-----------------------------------------------------|-------------------|---------------------------|---------------------------------------------------------------------------------|--------------|--------------------------------------------------------------------------|
| Chronic obstructive pulmonary disease (COPD) sensitive definition | 1                                                   | 491, 492, 496/J41–J44 | 491, 492, 496             | $\geq 1$ H or $\geq 1$ P                                                       | OHIP, DAD, SDS | Age of at least 35 years required                                          |
| Diabetes mellitus (DM)                   | 1                                                   | 250/E10, E11, E13, E14 | 250/Q040, K030, K029, K045, K046 | $\geq 1$ H or $\geq 2$ P or $\geq 1$ DM drug claim                              | OHIP, DAD, ODB | Gestational diabetes excluded                                            |
| Epilepsy                                 | 2                                                   | 345/G40           | 345                        | $\geq 1$ H or $\geq 3$ P                                                       | OHIP, NACRS, DAD | If determined on an outpatient basis, claims must be separated by $> 30$ days |
| Hyperlipidemia                           | 3                                                   | 272/E780, E782, E784, E785 | 272                        | $\geq 1$ H or $\geq 2$ P                                                       | OHIP, DAD     | Pregnancy-induced HTN excluded                                            |
| Hypertension (HTN)                       | 2                                                   | 401–405/110–113, I15 | 401–405                    | $\geq 1$ H or $\geq 2$ P                                                       | OHIP, DAD, SDS | If determined using OHIP claims, at least one must have been billed by a specialist or a family physician in a hospital or emergency room setting |
| Inflammatory bowel disease (IBD)         | 3                                                   | 555, 556/K50, K51  | 555, 556                   | $\geq 3$ H or $\geq 3$ P                                                       | OHIP, NACRS, DAD, SDS | If determined on an outpatient basis, at least one claim by a musculoskeletal specialist |
| Ischemic heart disease (IHD)             | 1                                                   | 410–414/120–125   | 410, 412, 413/R742, R743, Z434, G298 | $\geq 1$ H or $\geq 2$ P                                                       | OHIP, NACRS, DAD | If determined using OHIP claims, at least one must have been billed by a specialist or a family physician in a hospital or emergency room setting |
| Migraine                                 | 3                                                   | 346/G43           | 346                        | $\geq 1$ H or $\geq 2$ P                                                       | DAD, OHIP     |                                                                          |
| Mood/anxiety disorders                   | 1                                                   | 296, 300, 300.2, 300.3, 308.3, 309.0, 309.2, 309.3, 309.4, 309.8, 309.9, 311/F30-34, F38-43, F48.8, F48.9, F53.0, F93.1, F93.2 | 296, 300, 311 | $\geq 1$ H or $\geq 2$ P                                                       | OHIP, NACRS, DAD, OMHRS |                                                                          |
| Rheumatoid arthritis (RA)                | 2                                                   | 714/M05, M06      | 714                        | $\geq 1$ H or $\geq 3$ P                                                       | OHIP, DAD     | If determined on an outpatient basis, at least one claim by a musculoskeletal specialist |
| Schizophrenia (specific definition)      | 3                                                   | 295/F20, F25      | 295                        | $\geq 1$ H or $\geq 3$ P                                                       | OHIP, DAD, OMHRS |                                                                          |

ICD: International Classification of Disease; OHIP: Ontario Health Insurance Program; DAD: Discharge Abstract Database; SDS: same-day surgery; ODB: Ontario Drug Benefit Program; NACRS: National Ambulatory Care Reporting System; OMHRS: Ontario Mental Health Reporting System.
Malignancies were not included because the 3-year look-back period necessitated by the relatively brief medical history available in immigrants was thought to be insufficient for accurate ascertainment of malignancy history by virtue of the lower incidence and potential absence of any related healthcare claims for individuals in long-term remission.

**Covariates**

Total comorbidity burden was assessed in terms of Aggregated Diagnosis Group (ADG) number, which is a validated system for classifying comorbidity burden in the ambulatory setting. ADGs are based on the John Hopkins ACG system version 10 using hospitalization and physician visit information from 2 years prior to the index visit.

Other variables collected included age at index date, rural versus urban residence, and neighborhood income quintile. For immigrants, we also examined age at arrival in Canada, refugee status, duration of Canadian residence, and region of origin.

We determined potential confounders including age, sex, and socioeconomic status (SES), as measured by neighborhood income quintile, based on a review of the literature. Sex and age are known to independently affect both immigrant status and comorbidity. SES is known to affect comorbidity and may independently affect immigrant status due to preferential selection of skilled workers among immigrants to Canada.

**Analysis**

Baseline characteristics of immigrants with MS were summarized using descriptive statistics on the MS index date and compared to the control immigrant population. We also compared long-term residents on MS index date to controls without MS.

Prevalence ratios (PRs) were determined for each comorbidity in immigrants with versus without MS, and in long-term residents with versus without MS. A univariate generalized linear regression model with a Poisson distribution was used for calculation of PRs. Given the matched study design and equal duration of follow-up in all groups, these models effectively controlled for age, sex, and place of residence. We also created multivariable models to control for age, sex, place of residence, and SES. The models were run for three different PR comparisons: (1) immigrants with MS versus immigrant controls, (2) long-term residents with MS versus long-term resident controls, and (3) immigrants with MS versus long-term residents with MS. Model underdispersion was accounted for by adjusting estimated errors using Pearson chi-square over degrees of freedom as the dispersion parameter. We also repeated the analysis stratified by sex given prior literature suggesting sex differences in comorbidities associated with MS.

Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).

This study was approved by the research ethics board at St. Michael’s Hospital in Toronto, Ontario, Canada. Informed consent by participants was not required. ICES is a prescribed entity under section 45 of Ontario’s Personal Health Information Protection Act. Section 45 authorizes ICES to collect personal health information without consent for the purpose of analysis or compiling statistical information with respect to the management of, evaluation, or monitoring of the allocation of resources to or planning for all or part of the health system. This project was conducted under section 45, and approved by the Privacy and Compliance Office of ICES.

**Results**

**Study cohorts**

We identified 25,269 incident MS cases including 1538 (6.1%) in immigrants and 23,731 (93.9%) in long-term residents (Figure 1). Immigrant (n = 1534) and long-term resident (n = 23,731) MS cases were successfully matched to 4585 and 71,193 controls, respectively; four cases of MS in immigrants went unmatched. As compared to immigrants without MS, immigrants with MS were more likely to live in high-income neighborhoods, have immigrated from Europe, or the Middle East and Africa, and had a higher mean overall comorbidity burden (Table 2). As compared to long-term residents with MS, immigrants with MS were slightly younger, less likely to dwell in rural areas, less likely to live in high-income neighborhoods, and had a higher mean comorbidity burden.

**Comorbidities**

The most common comorbidities in immigrants with MS were mood and anxiety disorders (27.4%), hypertension (9.1%), hyperlipidemia (4.7%), and migraine (4.7%; Table 3).

As compared to immigrants without MS, immigrants with MS had a significantly higher prevalence of COPD, diabetes, hypertension, IHD, epilepsy,
migraine, mood and anxiety disorders, schizophrenia, RA, and IBD (Table 3). Long-term residents with MS had a higher prevalence of these same conditions compared to those without MS. Relative to long-term residents with MS, immigrants with MS did not show any significant differences in the prevalence of diabetes, hypertension, IHD, migraine, or schizophrenia but exhibited a lower prevalence of COPD, epilepsy, IBD, and mood and anxiety disorders, and a higher prevalence of hyperlipidemia and RA. Comorbidity patterns were generally similar in immigrant women and men with MS (Figure 2).

**Discussion**

To our knowledge, this is the first population-based study to investigate comorbidity patterns in immigrants with MS. All the comorbidities studied (with the exception of hyperlipidemia) were more frequently observed in immigrants at MS diagnosis relative to their corresponding controls, including COPD, diabetes, hypertension, IHD, epilepsy, migraine, mood and anxiety disorders, schizophrenia, RA, and IBD. While similar to long-term residents with MS, the high prevalence of comorbidities in immigrants with MS is particularly striking given the

---

**Figure 1.** Cohort selection flowchart. The flowchart demonstrates how the study cohort was selected.
low prevalence of medical conditions in immigrant controls and the “healthy immigrant effect”—reflecting the tendency of migrants to be healthier, wealthier, and better educated than the general population.21 Comorbidities are recognized to be common at diagnosis in the general MS population and are associated with delayed diagnosis,22,23 greater incidence of inflammatory disease activity,24 decreased initiation of disease-modifying therapy (DMT),25 and more rapid disability accrual.26 Since immigrants may already be at risk for delays in diagnosis and treatment due to language, cultural, and financial barriers27,28, it is important that clinicians be aware of comorbidities associated with MS in immigrants and strive for early identification and management.

Mood and anxiety disorders were the most prevalent comorbidity observed in both immigrants and long-term residents with MS. Our findings echo a systematic review, which reported depression and anxiety

Table 2. Baseline characteristics of MS cases (immigrant vs long-term resident) and matched controls.

| Variable                        | Value      | Immigrant MS cases | Immigrant controls | LTR MS cases | LTR controls |
|---------------------------------|------------|---------------------|--------------------|--------------|-------------|
|                                 |            | N = 1534           | N = 4585           | N = 23,731   | N = 71,193  |
| Female                          | Number (%) | 1037 (67.6)        | 3101 (67.6)        | 16,539 (69.7)| 49,617 (69.7)|
| Age (years)                     | Mean ± SD  | 38.23 ± 10.34      | 38.19 ± 10.32      | 40.01 ± 11.04| 40.01 ± 11.04|
| Age group (years)               |            | 20–35              | 1956 (42.7)        | 8944 (37.7)  | 26,832 (37.7)|
|                                 |            | 36–50              | 2056 (44.8)        | 10,194 (43.0)| 30,582 (43.0)|
|                                 |            | 51–65              | 573 (12.5)         | 4593 (19.4)  | 13,779 (19.4)|
| Age on arrival in Canada        | Mean ± SD  | 26.02 ± 11.37      | 26.50 ± 10.99      | N/A          | N/A         |
| Rural residence                 | Number (%) | 37 (2.4)           | 94 (2.1)           | 3150 (13.3)  | 9450 (13.3) |
| Neighborhood income quintile    | 1          | 407 (26.5)         | 1324 (28.9)        | 4301 (18.1)  | 12,290 (17.3)|
|                                 | 2          | 268 (17.5)         | 981 (21.4)         | 4599 (19.4)  | 13,730 (19.3)|
|                                 | 3          | 309 (20.1)         | 869 (19.0)         | 4801 (20.2)  | 14,400 (20.2)|
|                                 | 4          | 327 (21.3)         | 812 (17.7)         | 5022 (21.2)  | 15,088 (21.2)|
|                                 | 5          | 222 (14.5)         | 587 (12.8)         | 4909 (20.7)  | 15,440 (21.7)|
| Refugee status                  | Number (%) | 280 (18.3)         | 819 (17.9)         |              |             |
| Region of origin                |            | Africa & Middle East | 356 (23.2)      | 628 (13.7)  |             |
|                                 | Americas   | 220 (14.3)         | 722 (15.7)         |              |             |
|                                 | Asia & Pacific | 288 (18.8)     | 1884 (41.1)        |              |             |
|                                 | Europe     | 560 (36.5)         | 1111 (24.2)        |              |             |
|                                 | Stateless  | 50 (3.3)           | 150 (3.3)          |              |             |
|                                 | United States of America | 60 (3.9) | 89 (1.9) |             |
| Years of Ontario residence      | <2         | 30 (2.0)           | 97 (2.1)           |              |             |
|                                 | 2–5        | 232 (15.1)         | 698 (15.2)         |              |             |
|                                 | 5–10       | 456 (29.7)         | 1392 (30.4)        |              |             |
|                                 | 10–15      | 338 (22.0)         | 1140 (24.9)        |              |             |
|                                 | 15+        | 473 (30.8)         | 1232 (26.9)        |              |             |
| Number of ADGs                  | Mean ± SD  | 8.05 ± 3.54        | 4.94 ± 3.35        | 7.49 ± 3.54  | 4.84 ± 3.34 |
| ADG, group                      | Median (IQR)| 8 (6–10)          | 5 (2–7)            | 7 (5–10)    | 4 (2–7)    |
|                                 | 1–4 ADGs   | 236 (15.4)         | 1734 (37.8)        | 4525 (19.1)  | 29,587 (41.6)|
|                                 | 5–9 ADGs   | 774 (50.5)         | 1941 (42.3)        | 12,589 (53.0)| 28,552 (40.1)|
|                                 | 10+ ADGs   | 511 (33.3)         | 449 (9.8)          | 6389 (26.9)  | 6695 (9.4)  |
|                                 | No ADGs    | 13 (0.8)           | 461 (10.1)         | 228 (1.0)   | 6359 (8.9)  |

MS: multiple sclerosis; LTR: long-term resident; SD: standard deviation; N/A: not available; IQR: interquartile range; ADG: Aggregated Diagnosis Group.

*Age at index date, that is, first demyelinating event for MS cases.
Table 3. Prevalence ratios of individual comorbidities comparing MS cases versus matched controls by immigrant status and immigrants with MS versus long-term residents with MS.

| Condition          | Immigrants | Long-term residents | Immigrants with MS vs LTR with MS |
|--------------------|------------|---------------------|-----------------------------------|
|                    | MS cases   | Controls            | adjusted Prevalence ratio (95% CI) | MS cases | Controls | adjusted Prevalence ratio (95% CI) | adjusted Prevalence ratio (95% CI) |
| COPD               | 23 (1.5%)  | 32 (0.7%)           | 2.15 (1.84, 2.51)<sup>a</sup>       | 634      | 1158     | 1.64 (1.58, 1.71)<sup>a</sup>       | 0.65 (0.55, 0.77)<sup>a</sup>     |
| Diabetes           | 28 (1.8%)  | 16 (0.4%)           | 5.23 (4.47, 6.13)<sup>a</sup>       | 433      | 465      | 2.79 (2.69, 2.90)<sup>a</sup>       | 1.05 (0.92, 1.21)                 |
|                    | 11 (0.7%)  | 9 (0.2%)            | 3.65 (3.09, 4.32)<sup>a</sup>       | 257      | 276      | 2.79 (2.68, 2.91)<sup>a</sup>       | 0.62 (0.51, 0.75)                 |
| Hypertension       | 139 (9.1%) | 356 (7.8%)          | 2.17 (1.03, 1.32)<sup>a</sup>       | 2316     | 5344     | 1.30 (1.26, 1.34)<sup>a</sup>       | 1.08 (0.97, 1.20)                 |
| IBD                | 6 (0.4%)   | 7 (0.2%)            | 2.56 (2.15, 3.05)<sup>a</sup>       | 163      | 381      | 1.28 (1.23, 1.34)<sup>a</sup>       | 0.60 (0.48, 0.73)                 |
| IHD                | 33 (2.2%)  | 61 (1.3%)           | 1.62 (1.39, 1.88)<sup>a</sup>       | 639      | 916      | 2.09 (2.02, 2.17)<sup>a</sup>       | 0.87 (0.76, 1.01)                 |
| Hyperlipidemia     | 72 (4.7%)  | 237 (5.2%)          | 0.91 (0.79, 1.05)                  | 761      | 2245     | 1.02 (0.98, 1.06)                   | 1.62 (1.45, 1.81)                 |
| Migraine           | 72 (4.7%)  | 67 (1.5%)           | 3.21 (2.81, 3.68)<sup>a</sup>       | 1246     | 1545     | 2.42 (2.34, 2.50)<sup>a</sup>       | 0.88 (0.77, 1.00)                 |
| Mood/anxiety       | 420 (27.4%)| 565 (12.3%)         | 2.22 (2.02, 2.44)<sup>a</sup>       | 7400     | 13292    | 1.67 (1.63, 1.71)<sup>a</sup>       | 0.87 (0.80, 0.94)<sup>d</sup>     |
| disorders          | 8 (0.5%)   | 10 (0.2%)           | 2.30 (2.02, 2.84)<sup>a</sup>       | 107      | 277      | 1.16 (1.11, 1.21)<sup>a</sup>       | 1.31 (1.12, 1.53)<sup>d</sup>     |
| Schizophrenia      | 13 (0.9%)  | 26 (0.6%)           | 1.49 (1.26, 1.77)<sup>a</sup>       | 159      | 309      | 1.54 (1.48, 1.61)<sup>a</sup>       | 1.10 (1.45, 1.58)<sup>d</sup>     |

MS: multiple sclerosis; LTR: long-term resident; CI: confidence interval; COPD: chronic obstructive pulmonary disease; IBD: inflammatory bowel disease; IHD: ischemic heart disease; RA: rheumatoid arthritis.

<sup>a</sup>p < 0.0001.
<sup>b</sup>Models for these conditions did not converge, in part, due to small absolute case numbers and thus no adjusted estimate could be generated.
<sup>c</sup>p < 0.05.
<sup>d</sup>p < 0.01.
disorders in 23.7% and 21.9%, respectively, of persons with MS. Mood and anxiety disorders have been observed as part of what is known as the MS prodrome with higher rates of utilization of mental health services preceding MS diagnosis by up to 5 years. The high PR (adjusted PR: 2.23) of mood and anxiety disorders in immigrants with MS also reflects the low prevalence of these conditions in immigrant controls (12.3% vs 18.7% of long-term resident controls). This finding has three important implications. First, neurologic symptoms in an immigrant patient with a mental health condition should not be dismissed as secondary to the mental health issue. If the clinical context is appropriate, the possibility of demyelinating disease should be considered and investigated with a brain magnetic resonance imaging (MRI). Second, clinicians need to be aware of the high prevalence of mood and anxiety disorders in both female and male immigrants newly diagnosed with MS and screen for these conditions. Immigrants may encounter unique barriers in accessing mental healthcare due to language difficulties, lack of health system literacy, and stigma toward mental health.

Figure 2. Prevalence ratios of individual comorbidities in MS cases versus matched controls by immigrant status and gender. This figure shows prevalence ratios for specific conditions in MS cases versus matched controls. For each condition, prevalence ratios are displayed for four different groups: immigrant women, long-term resident (LTR) women, immigrant men, and LTR men. For example, prevalence ratio for COPD immigrant women represents prevalence of COPD in immigrant women with MS divided by prevalence of COPD in immigrant women controls. Certain conditions (e.g. epilepsy, IBD, RA, schizophrenia) were omitted due to small absolute numbers of cases in the female and/or male immigrant cohorts and the resultant risk of loss of confidentiality. COPD: chronic obstructive pulmonary disease; HTN: hypertension; IHD: ischemic heart disease.

Legend for Figure 2:

- COPD Immigrant Women
- COPD LTR Women
- COPD Immigrant Men
- COPD LTR Men
- Diabetes Immigrant Women
- Diabetes LTR Women
- Diabetes Immigrant Men
- Diabetes LTR Men
- HTN Immigrant Women
- HTN LTR Women
- HTN Immigrant Men
- HTN LTR Men
- IHD Immigrant Women
- IHD LTR Women
- IHD Immigrant Men
- IHD LTR Men
- Hyperlipidemia Immigrant Women
- Hyperlipidemia LTR Women
- Hyperlipidemia Immigrant Men
- Hyperlipidemia LTR Men
- Migraine Immigrant Women
- Migraine LTR Women
- Migraine Immigrant Men
- Migraine LTR Men
- Mood/Anxiety Disorders Immigrant Women
- Mood/Anxiety Disorders LTR Women
- Mood/Anxiety Disorders Immigrant Men
- Mood/Anxiety Disorders LTR Men
problems in their communities. Third, clinicians should follow these patients closely and consider early intervention as mental health conditions have been associated with greater long-term disability in MS, and immigrants and non-White persons may already be at risk for earlier disability accumulation. In a large population-based cohort study of incident MS cases in Canada, psychiatric comorbidity was associated with subsequent greater accrual of neurologic disability as measured by the Expanded Disability Status Scale (EDSS). Another large cohort study in Sweden found that persons having MS with depression had a higher risk of reaching major disability milestones, including EDSS scores of 3.0, 4.0, and 6.0. Mood and anxiety disorders, as well as migraine, another prevalent comorbidity among our immigrant cohort, have been shown to be major causes of limited work activities in the Australian MS Longitudinal Study of 929 persons with MS. Depression, along with physical comorbidity, was correlated with decreased health-related quality of life in a Canadian cross-sectional study of 949 persons with MS.

Overall, depression and anxiety are known to be underdiagnosed and undertreated in individuals with MS. Brief, self-reported psychometric scales can assist with screening for these conditions. Pharmacotherapy, cognitive behavioral therapy, mindfulness-based therapy, and exercise programs may all offer therapeutic benefit although there is no gold standard approach to treatment. Psychiatric, cerebrovascular, cardiovascular, lung, diabetes, cancer, and Parkinson’s disease comorbidity, were found to predict earlier mortality in a large population-based Danish cohort study of nearly 9000 persons with MS. In our cohort, immigrants who developed MS had a higher prevalence of COPD, diabetes, hypertension, and IHD compared to immigrant controls. These conditions may share common risk factors with MS such as smoking and obesity and may be provoked or exacerbated by adoption of Western lifestyle habits. In addition, multiple studies have demonstrated that cardiovascular disease may exacerbate MS disease course. In one retrospective study of 251 MS subjects, a one-point increase in baseline Framingham cardiovascular risk score was associated with a 31% higher risk of relapse, 19% higher risk of reaching an EDSS score of 6.0, and 62% higher risk of DMT escalation over 5 years. A recent study using postmortem whole-body autopsy to assess vascular disease burden suggested an excessive burden of cerebral small vessel disease in persons with MS compared to controls who died at younger ages of ≤ 60 years. In a population-based study in the United Kingdom, persons with MS were found to have higher rates of macrovascular events and associated mortality than matched controls, which was irrespective of age and not fully accounted for by traditional vascular risk factors. However, since recognized vascular risk factors remain reversible targets with early intervention, clinicians should consider factors such as elevated blood pressure, obesity, and smoking soon after diagnosis in their MS patients, particularly in groups known to have increased susceptibility. High rates of cardiovascular disease have been observed in certain immigrant groups in Ontario, including those from South Asia and the Middle East.

The question of whether comorbidities lead to delays in MS diagnosis in immigrants merits further study. Comorbidity has been associated with delayed diagnosis in the overall MS population for both physical and mental health conditions. Reasons for delayed diagnosis have not been completely elucidated but may be due to misattribution of MS symptoms to an established medical condition by either the patient or healthcare provider. The potential for misattribution could be compounded in immigrants due to under-recognition of MS in non-White individuals.

Strengths of our study include the large population-based sample, linkage of national immigrant data with health administrative data sources, use of validated comorbidity algorithms, and long interval for determination of incident MS cases. Our study has some important limitations. We cannot exclude the possibility that some individuals in the non-MS group were diagnosed with MS before 1994 or before moving to Ontario; however, the required 3-year period with no demyelinating disease claims prior to study entry makes this unlikely. Our estimates reflect recent active comorbid conditions as algorithms were only applied to health administrative data for the 3 years prior to MS index date. Lifetime prevalence of these conditions would be considerably higher, but the look-back period was dictated by our cohort of interest, the brief duration of Canadian residence for many immigrants, and the need to ensure a common period of ascertainment in both immigrant and long-term resident cohorts. SES was considered as a potential confounder in our adjusted analysis since educational status and associated occupational skills can facilitate immigration into Canada, although it is possible that it might be on the causal pathway between immigrant status and comorbidity, which could lead to overadjustment bias. However, we note that adjusted and unadjusted PRs were very similar. Some immigrants were
excluded because of fewer than the 3 years of health coverage required for determination of comorbidities (Figure 1). Incident cases of MS in immigrants who arrived prior to 1985 would have been classified as long-term resident cases due to the lack of immigration data from this era, but we expect the number to have been small given that the average age of MS onset is young adulthood. Moreover, there is evidence that the health characteristics of immigrants become more similar over time to those born in Canada.42 Finally, we were not able to examine certain comorbidities including cancer or health behaviors such as smoking due to limitations of our data sources.

In summary, we found that immigrants with MS had an increased prevalence of COPD, diabetes, hypertension, IHD, epilepsy, migraine, mood and anxiety disorders, schizophrenia, RA, and IBD relative to immigrant controls. The same conditions were more prevalent in long-term residents with MS compared to controls, and mirrored findings from previous studies of comorbidities in the general MS population. Prevalence of most conditions was similar or only slightly lower in immigrants compared to long-term residents with MS diagnosis, despite the “healthy immigrant effect” observed in unaffected immigrants. Therefore, the high prevalence of comorbidities in immigrants at MS diagnosis is particularly noteworthy. Since comorbidities are associated with worse long-term outcomes, clinicians should aim for early identification and management of comorbid conditions in immigrants with MS.

Acknowledgements
We thank IQVIA Solutions Canada Inc. for use of their Drug Information File.

Author Contributions
D.R. wrote the original grant proposal and drafted the manuscript. All authors had a role in study design, interpretation of the data, and manuscript review and approval. J.G. and P.P. performed the analyses.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dalia Rotstein has received research support from the Consortium of Multiple Sclerosis Centers (CMSC), the Multiple Sclerosis Society of Canada, and Roche. She has served as a speaker or consultant for Alexion, Biogen, EMD Serono, Novartis, Roche, and Sanofi Aventis. Colleen Maxwell has received research funding from the Canadian Institutes of Health Research, P.S.I. Foundation, MS Society of Canada, Consortium of MS Centers, MS Scientific Research Foundation, Ontario Ministry of Health and Long-Term Care Health System Research Fund, Canadian Frailty Network, Partners for Canadian Consortium on Neurodegeneration in Aging, Network for Aging Research-University of Waterloo. She is supported by a University Research Chair at the University of Waterloo. Karen Tu has received research funding from the Department of Defense United States of America, MaRS Innovation Fund, Canadian Institutes of Health Research (CIHR), Rathlyn Foundation, Canadian Dermatology Foundation, Canadian Rheumatology Association (CRA), Canadian Initiative for Outcomes in Rheumatology Care (CIORA), Toronto Rehab Institute Chair Fund, University of Toronto Practice-Based Research Network (UTOPIAN), PSI Foundation, Cancer Care Ontario (CCO) Clinical Programs & Quality Initiatives, Arthritis Society, McLaughlin Centre Accelerator Grant, MS Society of Canada and Consortium of MS Centers, Ontario SPOR Support Unit, Ontario Institute for Cancer Research (OICR) Health Services Research Program, Vascular Network, COVID-19 Pandemic Response and Impact Grant Program (Co-RIG), and Heart and Stroke Foundation of Ontario. She also receives a research scholar award from the Department of Family and Community Medicine at the University of Toronto. Ruth Ann Marrie receives research funding from CIHR, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Crohn’s and Colitis Canada, National Multiple Sclerosis Society, CMSC and the US Department of Defense. She is supported by the Waugh Family Chair in Multiple Sclerosis. Jodi Gatley, Priscila Pequeno, and Alexander Kopp have nothing to disclose.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded through grants from the Multiple Sclerosis Society of Canada and the Consortium of Multiple Sclerosis Centers. The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to the data in the study and the corresponding author had the final responsibility for the decision to submit for publication. The sponsors played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. This study was supported by ICES, which is funded...
by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI) and Immigration, Refugees and Citizenship Canada (IRCC). However, the analyses, conclusions, opinions, and statements expressed in the material are those of the author(s), and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred.

ORCID iD
Ruth Ann Marrie https://orcid.org/0000-0002-1855-5595

References
1. Marrie RA, Patten SB, Tremlett H, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. *Neurology* 2016; 86: 1279–1286.

2. Persson R, Lee S, Yood MU, et al. Multi-database study of multiple sclerosis: Identification, validation and description of MS patients in two countries. *J Neurol* 2019; 266(5): 1095–1106.

3. Marrie RA, Horwitz RI, Cutter G, et al. Association between comorbidity and clinical characteristics of MS. *Acta Neurol Scand* 2011; 124(2): 135–141.

4. Palladino R, Marrie RA, Majeed A, et al. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. *JAMA Neurol* 2020; 77: 820–828.

5. Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. *Mult Scler* 2015; 21(3): 263–281.

6. Magyari M and Sorensen PS. Comorbidity in multiple sclerosis. *Front Neurol* 2020; 11: 851.

7. Marrie RA, Rudick R, Horwitz RI, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. *Neurology* 2010; 74: 1041–1047.

8. Tettey P, Siejkja D, Simpson S Jr, et al. Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. *Neuroepidemiology* 2016; 46(2): 106–113.

9. Ribbons KA, McElduff P, Boz C, et al. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. *PLoS ONE* 2015; 10: e0122686.

10. Rotstein D and Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nat Rev Neurol* 2019; 15(5): 287–300.

11. Rotstein DL, Marrie RA, Maxwell C, et al. MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada. *Neurology* 2019; 93: e2203–e2215.

12. Statistics Canada. Census profile, 2016 census, https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?lang=E&Geo1=PR&Code1=35&Geo2=PR&Code2=01&SearchText=ontario&SearchType=Begin&SearchPR=01&B1=All&TABID=1&type=0 (accessed 12 December 2020).

13. Rotstein DL, Marrie RA, Tu K, et al. Health service utilization in immigrants with multiple sclerosis. *PLoS ONE* 2020; 15(7): e0234876.

14. Tu JV, Chu A, Rezai MR, et al. The incidence of major cardiovascular events in immigrants to Ontario, Canada: The CANHEART Immigrant Study. *Circulation* 2015; 132: 1549–1559.

15. Yarnell CJ, Fu L, Manuel D, et al. Association between immigrant status and end-of-life care in Ontario, Canada. *JAMA* 2017; 318: 1479–1488.

16. Widdifield J, Ivers NM, Young J, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. *Mult Scler* 2015; 21(8): 1045–1054.

17. Bermel RA, Rae-Grant AD and Fox RJ. Diagnosing multiple sclerosis at a later age: More than just progressive myelopathy. *Mult Scler* 2010; 16(11): 1335–1340.

18. Austin PC and Walraven C. The mortality risk score and the ADG score: Two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. *Med Care* 2011; 49(10): 940–947.

19. Vyas MV, Austin PC, Fang J, et al. Immigration status, ethnicity, and long-term outcomes following ischemic stroke. *Neurology*. Epub ahead of print 20 January 2021. DOI: 10.1212/WNL.0000000000011451.

20. Ng E, Sanmartin C and Manuel DG. Hospitalization rates among economic immigrants to Canada. *Health Rep* 2017; 28: 3–10.

21. Gushulak B. Healthier on arrival? Further insight into the “healthy immigrant effect.” *CMAJ* 2007; 176: 1439–1440.
22. Marrie RA, Horwitz R, Cutter G, et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. *Neurology* 2009; 72: 117–124.

23. Thomann A, Sorensen PS, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. *Neurology* 2017; 89: 1668–1675.

24. Kowalec K, McKay KA, Patten SB, et al. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. *Neurology* 2017; 89: 2455–2461.

25. Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. *Neurology* 2016; 86: 1287–1295.

26. McKay KA, Tremlett H, Fisk JD, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. *Neurology* 2018; 90: e1316–e1323.

27. Lasser KE, Himmelstein DU and Woolhandler S. Access to care, health status, and health disparities in the United States and Canada: Results of a cross-national population-based survey. *Am J Public Health* 2006; 96(7): 1300–1307.

28. Zanchetta MS and Poureslami IM. Health literacy within the reality of immigrants’ culture and language. *Can J Public Health* 2006; 97(Suppl. 2): S26–S30.

29. Tremlett H and Marrie RA. The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. *Mult Scler* 2021; 27: 6–12.

30. Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: A matched cohort study. *Lancet Neurol* 2017; 16(6): 445–451.

31. Nardin C, Latarче C, Soudant M, et al. Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study. *PLoS ONE* 2018; 13(3): e0194115.

32. Amezcua L, Conti DV, Liu L, et al. Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis. *Mult Scler Relat Disord* 2015; 4(1): 25–30.

33. Seyman E, Jones A, Guenette M, et al. Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada. *Mult Scler* 2021; 27: 1027–1036.

34. Binzer S, McKay KA, Brenner P, et al. Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study. *Neurology* 2019; 93: e2216–e2223.

35. Chen J, Taylor B, Winzenberg T, et al. Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis. *Mult Scler* 2020; 26(12): 1550–1559.

36. Berrigan LI, Fisk JD, Patten SB, et al. Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. *Neurology* 2016; 86: 1417–1424.

37. Korostil M and Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. *Mult Scler* 2007; 13(1): 67–72.

38. Feinstein A, Magalhaes S, Richard JF, et al. The link between multiple sclerosis and depression. *Nat Rev Neurol* 2014; 10: 507–517.

39. Jones CD, Motl R and Sandroff BM. Depression in multiple sclerosis: Is one approach for its management enough? *Mult Scler Relat Disord* 2021; 51: 102904.

40. Petruzzo M, Reia A, Maniscalco GT, et al. The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis. *Eur J Neurol* 2021; 28: 893–900.

41. Geraldes R, Esiri MM, Perera R, et al. Vascular disease and multiple sclerosis: A post-mortem study exploring their relationships. *Brain* 2020; 143: 2998–3012.

42. Ng E. Canadian Health Measures Survey: A tool for immigrant health research? *Health Rep* 2015; 26(3): 3–9.